Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000358

Purpose

The purpose of this study is to determine the safety of lofexidine in the treatment of opiate withdrawal. Preliminary data will also be obtained to assess the ability of lofexidine to alleviate opiate withdrawal signs and symptoms.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Lofexidine	Phase I

Drug Information available for: Lofexidine Lofexidine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Safety Evaluation of Lofexidine for Treatment of Opioid Withdrawal

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	21 Years to 59 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000358

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

Charles O'Brien, M.D., Ph.D.

PDVAMC Treatment Research Center

More Information

Study ID Numbers:	NIDA-3-0012-7, Y01-3-0012-7
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000358
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin
Lofexidine
Opioid-Related Disorders

Additional relevant MeSH terms:

Neurotransmitter Agents
Disease
Adrenergic alpha-Agonists
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Narcotic Antagonists
Cardiovascular Agents

Antihypertensive Agents
Pharmacologic Actions
Adrenergic Agonists
Pathologic Processes
Sensory System Agents
Therapeutic Uses
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 15, 2009